Novo Nordisk A/S $NVO Holdings Decreased by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 81.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 472,124 shares of the company’s stock after selling 2,063,222 shares during the quarter. SG Americas Securities LLC’s holdings in Novo Nordisk A/S were worth $17,351,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. increased its stake in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares during the period. Capital International Investors lifted its stake in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $310,199,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after acquiring an additional 4,302,126 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent analyst reports. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Wolfe Research began coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $47.55 on Friday. The company has a 50-day moving average of $43.65 and a 200-day moving average of $45.81. The firm has a market cap of $212.32 billion, a price-to-earnings ratio of 11.16, a price-to-earnings-growth ratio of 4.24 and a beta of 0.78. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. Analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.